Release date: 9/1/2024
Expiration date: 9/1/2025
Activity Overview
Experts will discuss the mechanism of action of current and investigational complement inhibitors, including the rationale for their use and differences between them (eg, targeted proteins). Discussion will also review treatment approaches under investigation, such as neuroprotective treatments, gene therapies, and cell-based therapies, and whether there may be a rationale in eventually combining any treatments.
Target Audience
This activity is designed for ophthalmologists, retina specialists, optometrists, and other healthcare professionals involved in the care of patients with GA.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Describe the mechanism of action of complement inhibitors
- Review emerging pathways in treating GA
Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at [email protected].
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and International Healthcare Media dba International Healthcare Education. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE – Optometrists
AKH Inc., Advancing Knowledge in Healthcare designates this asynchronous activity for a maximum of 0.25 COPE credit hours. Optometrists should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support
This activity is supported by independent educational grants from Iveric Bio, Inc.
| DISCLOSURES | ||
| Name | Relationship | Commercial Interest |
| Katherine E. Talcott, MD, FASRS (faculty) | Consultant | Alimera, Allergan, Apellis, Bausch and Lomb, Eyepoint, Genentech, Outlook, Regeneron, Zeiss |
| Researcher | Regeneron, Regenxbio, Zeiss | |
| Speaker | Genentech, Iveric Bio/Astellas, Zeiss | |
| Jorge A. Fortun, MD (faculty) | Consultant | Apellis, Astellas |
| Dorothy Caputo, MA, BSN, RN – VP, Healthcare Continuing Education and Operations | N/A | Nothing to disclose |
| Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
| AKH Inc Staff and Planners | N/A | Nothing to disclose |
| International Healthcare Media dba International Healthcare Education Staff and Planners | N/A | Nothing to disclose |
Disclosures
None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
